Online citations, reference lists, and bibliographies.
← Back to Search

Efficacy And Safety Of First‐ Or Second‐line Irinotecan, Cisplatin, And Mitomycin In Mesothelioma

D. Fennell, J. Steele, J. Shamash, M. T. Evans, P. Wells, M. Sheaff, R. Rudd, J. Stebbing
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor. Treatment options remain limited and the outcome in recurrent disease is poor.
This paper references
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1200/JCO.1993.11.8.1559
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
A. Chahinian (1993)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1093/ANNONC/MDH356
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
E. Andreopoulou (2004)
10.1016/S1470-2045(05)70471-X
Survival from rare cancer in adults: a population-based study.
G. Gatta (2006)
10.3346/jkms.2005.20.6.966
Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study
J. Baek (2005)
10.1016/J.LUNGCAN.2005.05.007
A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
T. Berghmans (2005)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1038/bjc.1990.434
Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist.
J. de Haes (1990)
10.1200/JCO.2005.23.16_SUPPL.7310
Phase I study of CPT11 and cisplatin with concurrent radiotherapy and adjuvant CPT11/cisplatin in small-cell lung cancer, limited disease
G. Klautke (2005)
[Phase I study].
T. Taguchi (1995)
Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma.
A. Chahinian (1984)
10.1007/s10620-006-8001-3
A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors
M. Kulke (2006)
10.1016/J.RADONC.2006.06.002
The role of radiation therapy in malignant pleural mesothelioma: a systematic review.
Y. Ung (2006)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1002/cncr.22063
A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum‐based chemotherapy
H. Kim (2006)
10.1200/JCO.2005.01.082
Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Ji-Youn Han (2005)
10.1016/J.LUNGCAN.2006.06.002
Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.
Hye Cheol Jeong (2006)
Phase II trial of mitomycin in malignant mesothelioma.
D. Bajorin (1987)
Phase II trial of mitomycin in malignantmesothelioma
D Bajorin (1987)
10.1136/thorax.2003.009290
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112
M. Muers (2004)
10.1097/00000421-200210000-00012
Second-Line Chemotherapy With Irinotecan and Vinorelbine in Stage IIIB and IV Non–Small-Cell Lung Cancer: A Phase II Study
M. González Cao (2002)
10.1016/J.EJSO.2006.03.009
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
R. García-Carbonero (2006)
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia
AP Chahinian (1993)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
10.1136/BMJ.318.7188.901
Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer.
M. Bredin (1999)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.LUNGCAN.2006.04.012
Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
G. Klautke (2006)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited - disease small - cell
HC Jeong (2006)
10.1038/nrc1883
Measuring response in a post-RECIST world: from black and white to shades of grey
L. Michaelis (2006)
10.1002/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.0.CO;2-E
Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma
T. Nakano (1999)
10.1200/JCO.2005.03.3027
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
A. Bottomley (2006)
Mesothelioma mortality in Great Britain: estimating the future burden
Uk-Health-amp-Safety-Executive (2003)
10.1038/sj.bjc.6600934
IPM chemotherapy in cytokine refractory renal cell cancer
J. Shamash (2003)
10.3816/CLC.2005.N.020
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
P. Jänne (2005)
10.1016/J.LUNGCAN.2004.11.015
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
C. Porta (2005)
Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?
N. Vogelzang (1999)
10.1016/S1470-2045(04)01492-5
Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.
D. Fennell (2004)
10.1016/J.LUNGCAN.2004.11.003
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
D. Maziak (2005)
Experimental and clinical activity of mitomycin C and cisdiamminedichloroplatinum in malignant mesothelioma
AP Chahinian (1984)



This paper is referenced by
10.1002/pds.1376
Current awareness: Pharmacoepidemiology and drug safety
(2007)
10.1002/2211-5463.12985
Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells
Bo Han (2020)
Advances in the Medical Treatment of Malignant
Kazuya Fukuoka (2014)
Malignantpleuralmesothelioma: currenttreatmentsandemerging drugs
Carmen Belli (2009)
10.1016/j.ejca.2012.05.018
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.
J. Blayney (2012)
10.3779/j.issn.1009-3419.2010.10.14
[Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].
Arnaud Scherpereel (2010)
10.1111/cas.12061
Glutathione S‐transferase P1‐1 as a target for mesothelioma treatment
A. Luca (2013)
10.5772/32919
The Impact of Extracellular Low pH on the Anti-Tumor Efficacy Against Mesothelioma
Toshihiko Fukamachi (2012)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
10.1159/000127577
Mesothelioma and Asbestos-Related Pleural Diseases
L. Greillier (2008)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
10.1007/s13665-012-0010-4
Emerging therapies for malignant pleural mesothelioma
J. Quispel-Janssen (2012)
10.1002/ijc.22984
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer
D. Fennell (2007)
10.1016/j.critrevonc.2019.102815
Emerging therapies in malignant pleural mesothelioma.
M. Cinausero (2019)
Wczesne i odległe wyniki leczenia złośliwego międzybłoniaka opłucnej na podstawie analizy 170 przypadków
Bryl Maciej (2012)
10.1016/j.bbrc.2014.03.100
Sensitization of mesothelioma cells to platinum-based chemotherapy by GSTπ knockdown.
Jian-li Chen (2014)
10.1001/jamaoncol.2018.5428
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial
R. Hassan (2019)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1016/j.rmed.2018.06.026
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
F. Petrelli (2018)
10.1016/J.PNEUMO.2010.07.013
Traitement de seconde ligne dans le mésothéliome pleural malin. Étude rétrospective française (2005–2006)
J. Margery (2010)
10.2165/00003495-200767080-00005
Management Options for Malignant Pleural Mesothelioma
Ranjit K. Goudar (2012)
10.1007/s11864-008-0071-3
Systemic Treatments for Mesothelioma: Standard and Novel
H. Kindler (2008)
10.21037/TLCR.2018.07.08
The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey
Youssef Ben Bouazza (2018)
of Thoracic Surgeons for management of Malignant Pleural Mesothelioma
A. Scherpereel (2009)
10.2217/fon-2017-0224
Advances in systemic therapy for malignant mesothelioma: future perspectives.
N. Sobhani (2017)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
Advances in the Medical Treatment of Malignant Mesothelioma
K. Kuribayashi (2014)
10.1517/14728210903074563
Malignant pleural mesothelioma: current treatments and emerging drugs
C. Belli (2009)
10.21037/jtd.2017.10.19
Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
M. Cinausero (2018)
10.1016/j.lungcan.2013.11.011
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar